HF
NVNO

HRT Financial’s enVVeno Medical NVNO Stock Holding History

HRT Financial’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,407
Closed -$15K – 4436
2025
Q4 		$15K Sell
1,407
-168
-11% -$3.26K ﹤0.01% 3017
2025
Q3 		$49K Buy
+1,575
New +$161K ﹤0.01% 2606
2024
Q2 		– Sell
-396
Closed -$75K – 2832
2024
Q1 		$75K Buy
+396
New +$71.1K ﹤0.01% 1891

Other funds holding NVNO

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HRT Financial's NVNO Position: Q1 2026 in Review

HRT Financial sold out of enVVeno Medical (NVNO) in Q1 2026, closing a stake of 1,407 shares — an estimated $15K sold.

HRT Financial first reported a position in NVNO in Q1 2024 and held it in 3 quarters. The position peaked at $75K in Q1 2024. 17 funds tracked by Wall St. Rank hold NVNO as of Q1 2026.

  • HRT Financial reported no remaining enVVeno Medical position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 1,407 enVVeno Medical shares in Q1 2026, an estimated $15K.
  • HRT Financial first reported a position in enVVeno Medical in Q1 2024 and held it in 3 quarters.
  • HRT Financial's enVVeno Medical position peaked at $75K in Q1 2024.
  • 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.